2023
Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis
Morris M, Jain A, Sun B, Kurbatov V, Muca E, Zeng Z, Jin Y, Roper J, Lu J, Paty P, Johnson C, Khan S. Multi-omic analysis reveals metabolic pathways that characterize right-sided colon cancer liver metastasis. Cancer Letters 2023, 574: 216384. PMID: 37716465, PMCID: PMC10620771, DOI: 10.1016/j.canlet.2023.216384.Peer-Reviewed Original ResearchConceptsLiver metastasesColon cancer liver metastasisCancer liver metastasesSided colon cancerSubset of patientsGrowth factor betaMulti-omics analysisFatty acid oxidationMetastatic diseaseInferior survivalClinical differencesClinical behaviorUntargeted metabolomics analysisTumor behaviorColon cancerBile acidsTumor cell metabolismFactor betaPatientsMetastasisPI3K-AktReactive oxygen speciesMEK-ERKLiquid chromatography-mass spectrometryRCCImpact of COVID-19 on the gastrointestinal surgical oncology patient population
Bakkila B, Marks V, Kerekes D, Kunstman J, Salem R, Billingsley K, Ahuja N, Laurans M, Olino K, Khan S. Impact of COVID-19 on the gastrointestinal surgical oncology patient population. Heliyon 2023, 9: e18459. PMID: 37534012, PMCID: PMC10391949, DOI: 10.1016/j.heliyon.2023.e18459.Peer-Reviewed Original ResearchGI cancer surgeryPreoperative chemotherapyCancer surgerySurgical careCOVID-19 pandemicCOVID-19Tertiary referral centerOncology patient populationFirst COVID-19 waveGI cancer casesCOVID-19 burdenHigh COVID-19 burdenEmergency surgeryReferral centerCOVID-19 waveOncology visitsGastrointestinal cancerGI cancersPatient populationStudy criteriaCancer careTreatment characteristicsCancer casesCase volumePatientsSurgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States
Kerekes D, Frey A, Bakkila B, Kunstman J, Khan S. Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States. Journal Of Surgical Oncology 2023, 128: 790-802. PMID: 37435780, DOI: 10.1002/jso.27392.Peer-Reviewed Original ResearchConceptsGastroenteropancreatic neuroendocrine carcinomasGEP-NECSingle-site surgeryOverall survivalSurgical treatmentNeuroendocrine carcinomaMortality reductionSite surgeryPrimary siteNational Cancer DatabaseRetrospective cohort studyPrimary tumor typeSurgical resectionCohort studyAggressive diseaseSurgical interventionSurvival outcomesTreatment optionsCancer DatabaseSurgeryPatientsTumor typesNECStrongest predictorCarcinomaIdentifying Sex-Specific Cancer Metabolites and Associations to Prognosis
Shen X, Ma S, Khan S, Johnson C. Identifying Sex-Specific Cancer Metabolites and Associations to Prognosis. Learning Materials In Biosciences 2023, 271-299. DOI: 10.1007/978-3-031-44256-8_11.Peer-Reviewed Original ResearchMetabolomics dataSurvival analysisCancer metabolitesColorectal cancerCox proportional hazards regression analysisProportional hazards regression analysisHazards regression analysisSex-specific associationsClinical dataCancer patientsCancer prognosisCancerMetabolomicsMultiple comparisonsPrognosisAnalytical methodSurvivalOncology studiesPatientsAlternative analytical approachRegression analysisSex-specificMetabolitesSex interactionAssociation
2022
Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review
Shen X, Jain A, Aladelokun O, Yan H, Gilbride A, Ferrucci LM, Lu L, Khan SA, Johnson CH. Asparagine, colorectal cancer, and the role of sex, genes, microbes, and diet: A narrative review. Frontiers In Molecular Biosciences 2022, 9: 958666. PMID: 36090030, PMCID: PMC9453556, DOI: 10.3389/fmolb.2022.958666.Peer-Reviewed Original ResearchColorectal cancerCRC patientsNarrative reviewSex steroid hormone estrogenFemale CRC patientsAnti-tumor effectsPI3K/Akt/Sex-related influencesSex-related factorsAsparagine synthetase expressionSex-specific factorsClinical outcomesTumor burdenCRC progressionPoor prognosisHormone estrogenEstrogen receptorSOX12 expressionRole of sexTherapeutic useAkt/Cancer cellsSynthetase expressionL-asparaginasePatients
2021
Kynurenic acid may underlie sex-specific immune responses to COVID-19
Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Yan H, Ma S, Rattray NJW, Casanovas-Massana A, Israelow B, Klein J, Lucas C, Mao T, Moore AJ, Muenker MC, Oh JE, Silva J, Wong P, team Y, Ko AI, Khan SA, Iwasaki A, Johnson CH. Kynurenic acid may underlie sex-specific immune responses to COVID-19. Science Signaling 2021, 14: eabf8483. PMID: 34230210, PMCID: PMC8432948, DOI: 10.1126/scisignal.abf8483.Peer-Reviewed Original ResearchConceptsKynurenic acidImmune responseClinical outcomesSex-specific immune responsesT cell responsesPoor clinical outcomeCOVID-19 patientsCoronavirus disease 2019COVID-19Sex-related differencesMale patientsCytokine abundanceInflammatory cytokinesKynurenine ratioSerum metabolomeDisease 2019Sex-specific linkKynurenine aminotransferaseCell responsesOld malePatientsMalesOutcomesResponseMetabolites
2020
Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype
Cai Y, Rattray NJW, Zhang Q, Mironova V, Santos-Neto A, Hsu KS, Rattray Z, Cross JR, Zhang Y, Paty PB, Khan SA, Johnson CH. Sex Differences in Colon Cancer Metabolism Reveal A Novel Subphenotype. Scientific Reports 2020, 10: 4905. PMID: 32184446, PMCID: PMC7078199, DOI: 10.1038/s41598-020-61851-0.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerColorectal cancerCRC patientsColon cancer metabolismPoor clinical outcomePatient colon tumorsAsparagine synthetase expressionNovel subphenotypesClinical outcomesAmino acid uptakePoor survivalLower incidenceAnatomic locationHigh incidenceTherapeutic targetColon cancerCancer Genomic AtlasClinical importanceColon tumorsTumor progressionAberrant metabolismNormal tissuesPatientsSubphenotypesAcid uptakeLiver-first approach to stage IV colon cancer with synchronous isolated liver metastases
Kurbatov V, Resio BJ, Cama CA, Heller DR, Cha C, Zhang Y, Lu J, Khan SA. Liver-first approach to stage IV colon cancer with synchronous isolated liver metastases. Journal Of Gastrointestinal Oncology 2020, 11: 76-83. PMID: 32175108, PMCID: PMC7052756, DOI: 10.21037/jgo.2020.01.03.Peer-Reviewed Original ResearchLiver-first approachIsolated liver metastasesColon adenocarcinomaLiver metastasesMultivariable Cox proportional hazards analysisCox proportional hazards analysisNational Cancer DatabaseProportional hazards analysisRisk of deathCompletion resectionResection sequenceUpfront chemotherapyExtrahepatic metastasesMedian survivalClinical outcomesHepatic metastasesCAC patientsKaplan-MeierMetastatic tumorsCancer DatabaseColon cancerCAC casesPatientsMetastasisGreater likelihood
2019
Predictors of Lymph Node Involvement by Soft Tissue Sarcoma of the Trunk and Extremity: An Analysis of the National Cancer Database
Miccio JA, Jairam V, Gao S, Augustyn A, Oladeru OT, Onderdonk BE, Chowdhary M, Han D, Khan S, Friedlaender G, Lindskog DM, Desphande HA, Osborn H, Roberts KB, Patel KR. Predictors of Lymph Node Involvement by Soft Tissue Sarcoma of the Trunk and Extremity: An Analysis of the National Cancer Database. Cureus 2019, 11: e6038. PMID: 31824805, PMCID: PMC6886621, DOI: 10.7759/cureus.6038.Peer-Reviewed Original ResearchSoft tissue sarcomasPathologic nodal evaluationNational Cancer DatabaseLymphovascular invasionNodal evaluationRisk factorsMultivariable logistic regression modelExtremity STS patientsGrade 3 tumorsHigh-risk groupTrunk/extremitiesLogistic regression modelsNeoadjuvant therapyWorse survivalRetrospective reviewSTS patientsDistant metastasisMultivariable analysisEpithelioid histologyTissue sarcomasCancer DatabaseExclusion criteriaPatientsLNMMetastasisDigital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma
Kurbatov V, Balayev A, Saffarzadeh A, Heller DR, Boffa DJ, Blasberg JD, Lu J, Khan SA. Digital Inference of Immune Microenvironment Reveals Low-Risk Subtype of Early Lung Adenocarcinoma. The Annals Of Thoracic Surgery 2019, 109: 343-349. PMID: 31568747, DOI: 10.1016/j.athoracsur.2019.08.050.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma of LungAdultAgedCohort StudiesDatabases, FactualDisease-Free SurvivalFemaleHumansImmunotherapyKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingPneumonectomyPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentSurvival AnalysisTumor MicroenvironmentConceptsTumor immune microenvironmentImmune microenvironmentLung adenocarcinomaOverall survivalRisk groupsMast cellsCox proportional hazard modelingEarly-stage lung adenocarcinomaLow-risk subtypesKaplan-Meier analysisPathological staging systemProportional hazard modelingImproved clinical outcomesCancer immune microenvironmentImmune cell typesEarly lung adenocarcinomaActivation stateClinical outcomesValidation cohortMacrophage contentStaging systemMultivariable modelCIBERSORT analysisPatientsClinical decisionThe Role of Bowel Preparation in Open, Minimally Invasive, and Converted-to-Open Colectomy
Luo J, Liu Z, Pei KY, Khan SA, Wang X, Yang M, Wang X, Zhang Y. The Role of Bowel Preparation in Open, Minimally Invasive, and Converted-to-Open Colectomy. Journal Of Surgical Research 2019, 242: 183-192. PMID: 31085366, DOI: 10.1016/j.jss.2019.02.039.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedAged, 80 and overAnti-Bacterial AgentsAntibiotic ProphylaxisCatharticsColectomyColonic DiseasesConversion to Open SurgeryElective Surgical ProceduresFemaleHospital MortalityHumansLaparoscopyLength of StayMaleMiddle AgedPostoperative ComplicationsPreoperative CareRetrospective StudiesRobotic Surgical ProceduresConceptsAntibiotic bowel preparationMechanical bowel preparationBowel preparationProtective effectElective colectomyPostoperative complicationsMajor complicationsReduced riskMultivariate logistic regression modelLength of stayStrong protective effectLogistic regression modelsStudy time periodInfectious complicationsAnastomotic leakOpen colectomyPreoperative strategyInvasive colectomyOpen groupColectomyAmerican CollegeComplicationsPatientsOverall populationRobotic surgery
2018
Defining Early-Onset Colon and Rectal Cancers
Jacobs D, Zhu R, Luo J, Grisotti G, Heller DR, Kurbatov V, Johnson CH, Zhang Y, Khan SA. Defining Early-Onset Colon and Rectal Cancers. Frontiers In Oncology 2018, 8: 504. PMID: 30460196, PMCID: PMC6232522, DOI: 10.3389/fonc.2018.00504.Peer-Reviewed Original ResearchEarly-onset colonRectal cancerCancer incidenceColon cancerEnd Results Program databaseSignet ring cell subtypeColorectal cancer incidenceRectal cancer incidenceColon cancer incidenceAdenocarcinoma histologyRectosigmoid locationBlack populationClinicopathological characteristicsClinicopathological featuresProgram databaseInclusion criteriaPercent changeColonCell subtypesCancerPatientsIncidence increasesIncidenceSimilar riseSuch cohortsNCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal Of The National Comprehensive Cancer Network 2018, 16: 693-702. PMID: 29891520, DOI: 10.6004/jnccn.2018.0056.Peer-Reviewed Original ResearchConceptsPrimary neuroendocrine tumorNeuroendocrine tumorsAdrenal tumorsManagement of NETsLocoregional advanced diseaseNCCN Guidelines InsightsAdrenal gland tumorsAdvanced diseaseNCCN guidelinesAdult patientsDistant metastasisGastrointestinal tractGland tumorsTumorsNeuroendocrineManagement optionsGuidelinesPatientsPheochromocytomaMetastasisParagangliomaDiseaseTractIntegrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis
Pitroda SP, Khodarev NN, Huang L, Uppal A, Wightman SC, Ganai S, Joseph N, Pitt J, Brown M, Forde M, Mangold K, Xue L, Weber C, Segal JP, Kadri S, Stack ME, Khan S, Paty P, Kaul K, Andrade J, White KP, Talamonti M, Posner MC, Hellman S, Weichselbaum RR. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis. Nature Communications 2018, 9: 1793. PMID: 29728604, PMCID: PMC5935683, DOI: 10.1038/s41467-018-04278-6.Peer-Reviewed Original ResearchConceptsColorectal liver metastasesLiver metastasesColorectal cancerOligometastatic colorectal cancerMetastatic colorectal cancerHigh-risk patientsSubset of patientsClinical risk stratificationTreatment of metastasesAngiogenic signatureVEGFA amplificationOligometastatic stateOverall survivalFavorable survivalRisk stratificationAdverse outcomesMetastatic cancerMolecular subtypesFocal therapyMetastasisPatientsMetastatic virulenceMolecular subtypingRobust subtypesCancer420 - Regional Differences in the Utilization of Palliative Care in Geriatric Colorectal Cancer Patients Requiring Emergent Surgery
Heller D, Jean R, Chiu A, Feder S, Kurbatov V, Cha C, Khan S. 420 - Regional Differences in the Utilization of Palliative Care in Geriatric Colorectal Cancer Patients Requiring Emergent Surgery. Gastroenterology 2018, 154: s-1269. DOI: 10.1016/s0016-5085(18)34158-1.Peer-Reviewed Original Research
2016
EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer
Khan SA, Zeng Z, Shia J, Paty PB. EGFR Gene Amplification and KRAS Mutation Predict Response to Combination Targeted Therapy in Metastatic Colorectal Cancer. Pathology & Oncology Research 2016, 23: 673-677. PMID: 28025786, PMCID: PMC5451302, DOI: 10.1007/s12253-016-0166-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Agents, ImmunologicalAntineoplastic Agents, PhytogenicAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCamptothecinCetuximabColorectal NeoplasmsDNA Mutational AnalysisErbB ReceptorsFemaleGene AmplificationGenes, p53HumansIrinotecanMaleMiddle AgedMutationRas ProteinsConceptsCombination biologic therapyMetastatic colorectal cancerIrinotecan-refractory colorectal cancerRefractory colorectal cancerColorectal cancerEGFR gene amplificationBiologic therapyKRAS mutationsIrinotecan-refractory metastatic colorectal cancerRefractory metastatic colorectal cancerCombination Targeted TherapyGene amplificationPhase II trialEGFR copy numberII trialPredictive biomarkersPredictive markerTargeted therapyTreatment responseBRAF mutationsBevacizumabPatientsCetuximabTumor tissueTherapy
2012
Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs
Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich J, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR. Oligo- and Polymetastatic Progression in Lung Metastasis(es) Patients Is Associated with Specific MicroRNAs. PLOS ONE 2012, 7: e50141. PMID: 23251360, PMCID: PMC3518475, DOI: 10.1371/journal.pone.0050141.Peer-Reviewed Original ResearchConceptsMetastatic progressionWidespread metastatic diseaseLower ratesPolymetastatic progressionCurative intentInitial metastasisMetastatic diseaseSurgical resectionMetastasis samplesLimited progressionPatientsDistinct entityProgressionLatter groupRecurrenceMetastasisHigh rateIndependent validation datasetExpression patternsOligometastasesResectionMicroRNAsRadiotherapyLungValidation dataset
2011
MicroRNA Expression Characterizes Oligometastasis(es)
Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR. MicroRNA Expression Characterizes Oligometastasis(es). PLOS ONE 2011, 6: e28650. PMID: 22174856, PMCID: PMC3236765, DOI: 10.1371/journal.pone.0028650.Peer-Reviewed Original ResearchConceptsOligometastatic patientsMetastasis-directed treatmentMetastasis-directed therapyHigh-dose radiotherapyPredictors of progressionMicroRNA-200 (miR-200) familyPolymetastatic progressionMetastatic diseasePatient selectionLocal treatmentCancer stagingMetastatic outcomeXenograft modelMicroRNA classifierPatientsPolymetastasesTumor samplesOligometastasesCell linesTreatmentProgressionBiological basisRadiotherapyExpressionTherapy
2008
Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer
Khan SA, Idrees K, Forslund A, Zeng Z, Rosenberg S, Pincas H, Barany F, Offit K, LaQuaglia MP, Paty PB. Genetic variants in germline TP53 and MDM2 SNP309 are not associated with early onset colorectal cancer. Journal Of Surgical Oncology 2008, 97: 621-625. PMID: 18381604, PMCID: PMC4381874, DOI: 10.1002/jso.20996.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerOnset colorectal cancerColorectal cancerMDM2 SNP309Age 30Germline variantsLi-Fraumeni kindredsP53 genePeripheral blood leukocytesNormal control populationP53 pathway genesFrequency of polymorphismsGermline TP53Blood leukocytesRare diseaseSNP309Control populationTissue availabilityPatientsConstitutional mutationsDisease susceptibilityCancerP53DiseaseGenetic variants